[High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy]

Urologe A. 2020 Apr;59(4):478-479. doi: 10.1007/s00120-020-01160-6.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / pathology
  • Humans
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use*
  • Quinoxalines / therapeutic use*
  • Treatment Outcome
  • Urologic Neoplasms / drug therapy*
  • Urologic Neoplasms / pathology
  • Urothelium / pathology*

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Quinoxalines
  • erdafitinib